Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | GCGR | P47871 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4407535 | 0.86 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11ALOX5 | |
| SCHEMBL4408131 | 0.81 | MAPK14 (0.46) | MAPK14ALDH1A1ROCK1LMNA | |
| SCHEMBL4408109 | 0.76 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11ALOX5 | |
| SCHEMBL4417408 | 0.76 | MAPK14 (0.41) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4410189 | 0.75 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11ALOX5 | |
| SCHEMBL4417405 | 0.71 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11ALOX5 | |
| SCHEMBL4409114 | 0.70 | HTR3A (0.47) | MAPK14MAPK13MAPK12MAPK11ALOX5 | |
| SCHEMBL25277120 | 0.70 | PKN1 (0.58) | MAPK14MAPK13MAPK12MAPK11ALOX5 | |
| SCHEMBL25246683 | 0.66 | MAPT (0.54) | MAPK14MAPK13MAPK12MAPK11ALOX5 | |
| SCHEMBL30406302 | 0.66 | MAPT (0.54) | MAPK14MAPK13MAPK12MAPK11ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2008-12-25 | — | — | US | claimed |
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-10-22 | — | — | US | disclosed |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2008-12-25 | — | — | US | disclosed |
| EP-1833828-A2 | CONDENSED PYRIDINES AS KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006013095-A2 | CONDENSED PYRIDINES AS KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | MAPK1, MAP4K2, MAP3K1 | MAPK14 36/4885MAPK13 39/4885MAPK12 41/4885 |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | MAPK1, MAP4K2, MAP3K1 | MAPK14 36/4885MAPK13 39/4885MAPK12 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.